[go: up one dir, main page]

PE20010316A1 - GENE DERIVED FROM LAWSONIA AND RELATED POLYPEPTIDES, PEPTIDES AND PROTEINS AND THEIR USES - Google Patents

GENE DERIVED FROM LAWSONIA AND RELATED POLYPEPTIDES, PEPTIDES AND PROTEINS AND THEIR USES

Info

Publication number
PE20010316A1
PE20010316A1 PE2000000446A PE0004462000A PE20010316A1 PE 20010316 A1 PE20010316 A1 PE 20010316A1 PE 2000000446 A PE2000000446 A PE 2000000446A PE 0004462000 A PE0004462000 A PE 0004462000A PE 20010316 A1 PE20010316 A1 PE 20010316A1
Authority
PE
Peru
Prior art keywords
polypeptide
intracellularis
lawsonia
refers
sequence
Prior art date
Application number
PE2000000446A
Other languages
Spanish (es)
Inventor
Michael Panaccio
Everett Lee Rosey
Detlef Hasse
Robert Gerard Ankenbauer
Meri Sinistaj
Jim Parsons
Original Assignee
Pfizer Prod Inc
Agriculture Victoria Serv Pty
Pig Res And Dev Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc, Agriculture Victoria Serv Pty, Pig Res And Dev Corp filed Critical Pfizer Prod Inc
Publication of PE20010316A1 publication Critical patent/PE20010316A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UN POLIPEPTIDO INMUNOGENICO AISLADO O RECOMBINANTE CARACTERIZADO PORQUE TIENE UNA REACCION CRUZADA CON UN EPITOPE DE CELULA B O CELULA T DE UN POLIPEPTIDO LAWSONIA SPP FlgE DE PREFERENCIA L. INTRACELLULARIS, SE CARACTERIZA POR PROVOCAR LA PRODUCCION DE ANTICUERPOS, CONFERIR UNA RESPUESTA INMUNOLOGICA PROTECTORA EN UN ANIMAL, PORCINO, AVE; INDUCIR INMUNIDAD HUMORAL; ES SELECCIONADO DE: a)UN PEPTIDO, OLIGOPEPTIDO, POLIPEPTIDO QUE COMPRENDE UNA SECUENCIA DE AMINOACIDOS QUE TIENE AL MENOS 60% DE IDENTIDAD DE LA SECUENCIA No ID SEC:1 DE 502 AMINOACIDOS O LA SECUENCIA DE AMINOACIDOS CODIFICADA POR LA SECUENCIA DE NUCLEOTIDOS QUE CODIFICA FlgE DE pALK11 (ATCC 207156); b)UN HOMOLOGO, ANALOGO, DERIVADO QUE IMITA A UN EPITOPE DE CELULA B O T DE UN POLIPEPTIDO DE LAWSONIA SPP. SE REFIERE TAMBIEN A UNA VACUNA QUE COMPRENDE ADEMAS OTRO COMPONENTE INMUNOGENICO QUE COMPRENDE UN PEPTIDO O PROTEINA DE L. INTRACELLULARIS ANTIGENICA DE PREFERENCIA OmPh, SodC, HEMOLISINA, AUTOLISINA; TAMBIEN SE REFIERE A UN VECTOR QUE COMPRENDE UN ACIDO NUCLEICO CON UNA SECUENCIA QUE CODIFICA AL POLIPEPTIDO; UN ACIDO NUCLEICO AISLADO QUE CODIFICA AL POLIPEPTIDO; UN PLASMIDO pALK11. EL POLIPEPTIDO CODIFICADO DE UN GEN DERIVADO DE LAWSONIA PUEDE SER UTIL PARA EL TRATAMIENTO DE ENFERMEDAD INTESTINAL EN ANIMALES Y PAJAROSIT REFERS TO AN ISOLATED OR RECOMBINANT IMMUNOGENIC POLYPEPTIDE CHARACTERIZED BECAUSE IT HAS A CROSS-REACTION WITH AN EPITO CELL B OR CELL T OF A LAWSONIA SPP FlgE POLYPEPTIDE OF PREFERENCE L. INTRACELLULARIS PROVIDES AN INTRACELLULARIS PROVIDED FOR AN INTRACELLULARIS PROVIDED PROTECTION. AN ANIMAL, PORCINE, AVE; INDUCE HUMORAL IMMUNITY; IT IS SELECTED FROM: a) A PEPTIDE, OLIGOPEPTIDE, POLYPEPTIDE THAT COMPRISES A SEQUENCE OF AMINO ACIDS THAT HAS AT LEAST 60% IDENTITY OF THE SEQUENCE NO. PALK11 FlgE (ATCC 207156); b) A HOMOLOGICAL, ANALOGUE, DERIVATIVE THAT IMITATES A B OR T CELL EPITOPE OF A LAWSONIA SPP POLYPEPTIDE. IT ALSO REFERS TO A VACCINE THAT ALSO INCLUDES ANOTHER IMMUNOGENIC COMPONENT INCLUDING A PEPTIDE OR PROTEIN OF THE ANTIGENIC L. INTRACELLULARIS OF PREFERENCE OmPh, SodC, HEMOLYSIN, AUTOLYSIN; IT ALSO REFERS TO A VECTOR THAT INCLUDES A NUCLEIC ACID WITH A SEQUENCE THAT ENCODES THE POLYPEPTIDE; AN ISOLATED NUCLEIC ACID THAT ENCODES POLYPEPTIDE; A PLASMID pALK11. THE POLYPEPTIDE CODED FROM A LAWSONIA DERIVED GENE MAY BE USEFUL FOR THE TREATMENT OF INTESTINAL DISEASE IN ANIMALS AND BIRDS

PE2000000446A 1999-05-13 2000-05-12 GENE DERIVED FROM LAWSONIA AND RELATED POLYPEPTIDES, PEPTIDES AND PROTEINS AND THEIR USES PE20010316A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13397399P 1999-05-13 1999-05-13

Publications (1)

Publication Number Publication Date
PE20010316A1 true PE20010316A1 (en) 2001-03-15

Family

ID=22461178

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000446A PE20010316A1 (en) 1999-05-13 2000-05-12 GENE DERIVED FROM LAWSONIA AND RELATED POLYPEPTIDES, PEPTIDES AND PROTEINS AND THEIR USES

Country Status (9)

Country Link
EP (1) EP1181315A4 (en)
JP (1) JP2003516113A (en)
AU (1) AU771376B2 (en)
BR (1) BR0011294A (en)
CA (1) CA2372098A1 (en)
MX (1) MXPA01011669A (en)
NZ (1) NZ515331A (en)
PE (1) PE20010316A1 (en)
WO (1) WO2000069904A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6605696B1 (en) 1999-10-22 2003-08-12 Pfizer, Inc. Lawsonia intracellularis proteins, and related methods and materials
ES2360225T3 (en) 2000-12-20 2011-06-02 Intervet International Bv VACCINE AGAINST LAWSONIA INTRACELLULARIS.
DE602004024423D1 (en) * 2003-09-12 2010-01-14 Intervet Int Bv VACCINE WITH LAWSONIA INTRACELLULARIS SUB-UNIT
US8834891B2 (en) 2005-03-14 2014-09-16 Boehringer Ingelheim Vetmedica, Inc. Immunogenic compositions comprising Lawsonia intracellularis
US8398994B2 (en) 2005-07-15 2013-03-19 Boehringer Ingelheim Vetmedica, Inc. Lawsonia vaccine and methods of use thereof
EP2859900A1 (en) 2006-12-11 2015-04-15 Boehringer Ingelheim Vetmedica, Inc. Effective method of treatment of porcine circovirus and lawsonia intracellularis infections
CN114712392B (en) * 2022-05-16 2022-11-25 西部医美生物科技成都有限公司双流医疗分公司 Immune cell preparation from autologous blood separation and application thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5885823A (en) * 1995-06-05 1999-03-23 Nobl Laboratories, Inc. Lawsonia intracellularis cultivation, anti-Lawsonia intracellularis vaccines and diagnostic agents
CA2236574A1 (en) * 1995-11-30 1997-06-05 Daratech Pty. Ltd. Therapeutic and diagnostic compositions

Also Published As

Publication number Publication date
NZ515331A (en) 2003-07-25
JP2003516113A (en) 2003-05-13
BR0011294A (en) 2002-02-26
AU4385900A (en) 2000-12-05
EP1181315A4 (en) 2002-08-14
EP1181315A1 (en) 2002-02-27
MXPA01011669A (en) 2003-09-10
WO2000069904A1 (en) 2000-11-23
AU771376B2 (en) 2004-03-18
CA2372098A1 (en) 2000-11-23

Similar Documents

Publication Publication Date Title
BR9711090A (en) Isolated omp106 polypeptide or substantially pure antibody isolated peptide fragment of the omp106 polypeptide vaccine antigenic composition dna substantially pure process for producing an immune response in an animal and process for producing a non-hemagglutinating cultivar of m catarrhalis from a strain or cultivar of m catarrhalis ha
AR047345A1 (en) VACCINE TO IMPROVE THE GROWTH OF ANIMALS BASED ON NEUTRALIZING EPITHOPES
ATE319091T1 (en) DIAGNOSIS OF NATIVE SPRUE/CELIAC DISEASE USING GLIADINE PITOPES
BR0010720A (en) Antigenic neisseria peptides
BRPI0412799A (en) immunogen, composition, nucleic acid, recombinant cell, methods for preparing a polypeptide, for inducing a protective immune response in a patient and for inducing an anamnesic response in a patient, and optimized yeast nucleic acid sequence
DE69129865D1 (en) OSTEOGENEIC PEPTIDES
ATE299936T1 (en) FAS ANTIGEN DERIVATIVES
PE20010316A1 (en) GENE DERIVED FROM LAWSONIA AND RELATED POLYPEPTIDES, PEPTIDES AND PROTEINS AND THEIR USES
DE69836744D1 (en) GROUP A STREPTOKOKEN VACCINE
WO2002008716A3 (en) Method for screening peptides for use in immunotherapy
BR9710975A (en) Genes of 120 kda exposed surface adhesion protein immunodominant of ehrlichia chaffeensis
ATE154638T1 (en) MUTANTS OF INTERLEUKIN-3
BR0309491A (en) Vaccine composition, immunogenic composition, use of an e7 protein and neutralizing antibodies
PE20010237A1 (en) GENE DERIVED FROM LAWSONIA AND OmpH POLYPEPTIDES, PEPTIDES AND RELATED PROTEINS AND THEIR USES
PE20010238A1 (en) GENE DERIVED FROM LAWSONIA AND POLYPEPTIDES SodC, PEPTIDES AND RELATED PROTEINS AND THEIR USES
AU6961601A (en) Transport peptides among which c-terminal E<sup>rns</sup> peptide and analogues thereof
PE20010239A1 (en) GENE DERIVED FROM LAWSONIA AND RELATED POLYPEPTIDES, PEPTIDES AND PROTEINS OF HEMOLYSIN AND THEIR USES
DE69935599D1 (en) MODIFIED HCV PEPTIDE VACCINES
WO1999051188A3 (en) A polypeptide comprising the amino acid of an n-terminal choline binding protein a truncate, vaccine derived therefrom and uses thereof
ATE312923T1 (en) MORAXELLA CATARRHALIS BASB034 POLYPEPTIDES AND USES THEREOF
WO1998040497A3 (en) An ex vivo animal or challenge model as method to measure protective immunity directed against parasites and vaccines shown to be protective in said method
WO2003064446A3 (en) Plasma protein-binding peptides from bacterial curli
ATE174963T1 (en) CLONING AND EXPRESSION OF A RHOPTRY-ASSOCIATED PROTEIN FROM P. FALCIPARUM
Gao et al. Structure‐activity relationships of sialogogic heptapeptides analogous to physalaemin
AR004191A1 (en) POLYPEPTIDES TO INDUCE PROTECTIVE IMMUNITY AGAINST TUBERCULOSIS, DNA MOLECULES THAT CODES THEM, A VECTOR OF EXPRESSION, A HOST CELL, A VACCINE, A FUSION PROTEIN, A METHOD OF DETECTING TUBERCULOSIS

Legal Events

Date Code Title Description
FC Refusal